In a report released today, Oren Livnat from H.C. Wainwright reiterated a Buy rating on Lipocine (LPCN), with a price target of $5. The company’s shares closed yesterday at $2.23.
Livnat wrote:
“We view both developments, taken together, as boosts to the likelihood of Tlando final approval. We continue to expect Tlando NDA resubmission in early-2Q19, 4Q19 approval following a 6-month review and commercial partnering with peak partner sales over $300M (over $75M revenue to Lipocine). We do not believe that the earlier approval of a competing oral TRT (launch timing uncertain; Clarus states pharmacy availability “before year-end”) changes our thesis given: (1) the market is more than large enough to accommodate two oral players given over 7M TRT prescriptions in the U.S.”
According to TipRanks.com, Livnat is a 4-star analyst with an average return of 10.4% and a 53.2% success rate. Livnat covers the Healthcare sector, focusing on stocks such as Verrica Pharmaceuticals Inc, Taiwan Liposome Company Ltd, and Zynerba Pharmaceuticals.
Lipocine has an analyst consensus of Moderate Buy, with a price target consensus of $5.
See today’s analyst top recommended stocks >>
Based on Lipocine’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $3.23 million. In comparison, last year the company had a GAAP net loss of $5.33 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Lipocine, Inc. operates as a pharmaceutical company, which engages in the research and development of treatment for use in men’s and women’s health through proprietary drug delivery technologies. It focuses on the oral testosterone replacement therapy and preterm birth prevention. The company was founded in 2011 and is headquartered in Salt Lake City, UT.
